medigraphic.com
ISSN 2448-8909 (Print)

2021, Number 6

<< Back Next >>

Med Crit 2021; 35 (6)

From complex to simple... lactic dehydrogenase as a severity marker in patients with SARS-CoV-2 infections

Guerrero THE, Gómez GMN, Hernández PAE, Jiménez CC

Language: Spanish
References: 32
Page: 319-328
PDF size: 262.83 Kb.


ABSTRACT

Introduction: The reference standard for the diagnosis of COVID-19 remains reverse transcriptase polymerase chain reaction (RT-PCR)-positive, while plain chest computed tomography (CT) has been more sensitive and specific in severity classification. In defining the severity of SARS-CoV-2, clinical, imaging and laboratory criteria have been specified, mentioning several markers, including lactate dehydrogenase (LDH). Historically, LHD has been of interest as a biomarker associated with lung damage, with a greater peak during the influenza A H1N1 pandemic, and taken as a marker in the definition of severity. Objective: To determine the diagnostic performance of serum LHD levels on admission to the ICU as a marker of severity in patients with SARS-CoV-2 infection. Material and methods: Observational, analytical, longitudinal and prospective study, carried out in two stages, the first (April 1, 2020 to September 30, 2020) consisted of a correlation study between serum LHD levels at Intensive Care Unit (ICU) admission and simple chest CT, a moderate correlation was obtained between serum LHD levels and severity score by pulmonary tomography, with an r = 0.5 and p < 0.0001; a severity-associated serum LHD cut-off point of 396 U/dL was obtained (p < 0.001, sensitivity 86.02%, specificity 75%). The second stage was extended until December 31, 2020, in which analysis is performed for diagnostic test performance, in inferential statistics correlation tests are performed, a multiple linear regression model is built, analysis was performed for diagnostic tests by building two-by-two contingency tables, determining sensitivity, specificity, positive predictive value, negative predictive value, likelihood ratios and Bayesian analysis. Results: 155 patients were included in the study to determine the diagnostic performance of serum LHD levels in patients with severe SARS-CoV-2 infection; by multiple linear regression analysis, it was determined that LHD levels on admission to the ICU is a predictor of severity in patients with SARS-CoV-2. A sensitivity of 0.92, specificity 0.41, with PPV 0.854, NPV 0.57 and an accuracy of 0.83, an LR + 1.57 and LR- 0.63 were obtained. In the post-test probability results, patients with DHL > 396 U/dL have a 86.3% probability of developing severe COVID-19. DHL levels have a direct correlation with ICU days of stay and days of invasive mechanical ventilation with statistical significance (p = 0.001, p = 0.033 respectively). Conclusion: Serum LHD levels have a high sensitivity to diagnose COVID-19 severity; and in the absence of simple chest CT, it can predict severe lung damage. It constitutes a test with high screening power in severe cases of COVID-19; with a probability of almost double (LR + 1.6) that of predicting a severe case.


REFERENCES

  1. COVID-19 cases and deaths reported by countries and territories in the Americas Last. [Updated: 1 Aug 2020]. Please visit the PAHO COVID-19 Geo-HUB for recent information. Available in: https://paho-covid19-response-who.hub.arcgis.com/

  2. Li Y, Yao L, Li J, et al. Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19. J Med Virol. 2020;92(7):903-908.

  3. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513.

  4. Tan L, Kang X, Ji X, et al. Validation of predictors of disease severity and outcomes in COVID-19 patients: a descriptive and retrospective study. Med (NY). 2020;1(1):128-138.e3.

  5. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733.

  6. Elizalde GJ, Fortuna CJ, Luviano GJ, et al. Guía COVID-19 para la atención del paciente crítico con infección por SARS-CoV-2 Colegio Mexicano de Medicina Crítica. Med Crit. 2020;34(1):7-42.

  7. Aranda E. Interpretación de la deshidrogenasa láctica. Rev Bol Ped. 2010;49(2):132-144.

  8. Sánchez NM, Olive AC, Peña CM, et al. Isoenzimas de lactato deshidrogenasa en el suero y aspirado bronquial de recién nacidos con dificultad respiratoria de etiología diversa. An Esp Pediatr. 1996;45:62-66.

  9. Kelly R, Greiff D. The level of lactic dehydrogenase activity as an indicator of the grwoth of influenza virus in the embryonate egg. J Exp Med. 1961;113(1):125-129.

  10. Caprotta G, González P, Primucci Y, et al. Infección respiratoria por influenza A H1N1 en cuidados intensivos de la República Argentina. An Pediatr (Barc). 2010;72(1):62-66.

  11. Adeva M, López M, Funcasta R, et al. Comprehensive review on lactate metabolism in human health. Mitochondrion. 2014;17:76-100.

  12. Glick JH Jr. Serum lactate dehydrogenase isoenzyme and total lactate dehydrogenase values in health and disease, and clinical evaluation of these tests by means of discriminant analysis. Am J Clin Pathol. 1969;52(3):320-328.

  13. Wu LW, Kao TW, Lin CM, et al. Examining the association between serum lactic dehydrogenase and all-cause mortality in patients with metabolic syndrome: a retrospective observational study. BMJ Open. 2016;6(5):e011186.

  14. García A, Rosas M, Santoyo A, et al. Deshidrogenasa láctica como factor pronóstico en neumonías. Med Int Mex. 2017;33(5):563-571.

  15. Neri S, Barranco G, León M, et al. Factores predictores de defunción en pacientes con neumonía por influenza A H1N1. Med Int Mex. 2011;27(5):421-428.

  16. Lu J, Wei Z, Jiang H, et al. Lactate dehydrogenase is associated with 28 day mortality in patients with sepsis: a retrospective observational study. J Surg Res. 2018;228:314-321.

  17. Ma C, Gu J, Hou P, et al. Incidence, clinical characteristics and prognostic factor of patients with COVID-19: a systematic review and meta-analysis. medRxiv. 2020.

  18. Han Y, Zhang H, Mu S, et al. Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study. Aging (Albany NY). 2020;12(12):11245-11258.

  19. Gobierno de México. Boletín estadístico sobre exceso de mortalidad por todas las causas durante la emergencia por COVID-19 2020.

  20. Vaduganathan M, Vardeny O, Michel T, et al. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382(17):1653-1659.

  21. Gandhi R, Lynch J, Del Rio C. Mild or moderate Covid-19. N Engl J Med. 2020;383(18):1757-1766.

  22. Verity R, Okell L, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20:669-677.

  23. Francone M, Iafrate F, Masci GM, et al. Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. Eur Radiol. 2020;30(12):6808-6817.

  24. Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing for coronavirus disease 2019 (COVID-19) in China: a report of 1,014 cases. Radiology. 2020;296(2):E32-E40.

  25. Prokop M, Van Everdingen W, Van Rees Vellinga T, et al. CO-RADS: a categorical CT assessment scheme for patients suspected of having COVID-19-definition and evaluation. Radiology. 2020;296(2):E97-104.

  26. Tjendra Y, Al Mana AF, Espejo AP, et al. Predicting disease severity and outcome in COVID-19 patients: a review of multiple biomarkers. Arch Pathol Lab Med. 2020;144(12):1465-1474.

  27. Ferrando C, Mellado R, Gea A, et al. Características, evolución clínica y factores asociados a la mortalidad en UCI de los pacientes críticos infectados por SARS-CoV-2 en España: estudio prospectivo, de cohorte y multicéntrico. Rev Esp Anestesiol Reanim. 2020;67(8):425-437.

  28. Iba T, Levy J, Levi M et al. Coagulopathy of coronavirus disease 2019. Crit Care Med. 2020;48(9):1358-1364.

  29. Fink M. Cytopathic hypoxia. Mitochondrial dysfunction as mechanism contributing to organ dysfunction in sepsis. Crit Care Clin. 2001;17(1):219-237.

  30. Fernández J, Hinestroza L, Villasmil E, et al. Deshidrogenasa láctica sérica en pacientes con neumonía adquirida en la comunidad. Pulmón 6. 2015.

  31. Garrido C, Cano C, Salcedo M, et al. Influenza A H1N1 (swine flu) en niños estudiados en el Instituto Nacional de Enfermedades Respiratorias. Acta Pediatr Mex. 2010;31(4):162-167.

  32. Ji D, Zhang D, Xu J, et al. Prediction for Progression Risk in Patients With COVID-19 Pneumonia: The CALL Score. Clin Infect Dis. 2020;71(6):1393-1399.




2020     |     www.medigraphic.com